Please login to the form below

Not currently logged in
Email:
Password:

Tracleer

This page shows the latest Tracleer news and features for those working in and with pharma, biotech and healthcare.

J&J agrees $30bn deal to acquire Actelion

J&J agrees $30bn deal to acquire Actelion

Meanwhile, J&J claims the company's marketed products including its trio of pulmonary artery hypertension (PAH) drugs, including Tracleer (bosentan) - now facing generic competition - as well as follow-up drugs

Latest news

More from news
Approximately 7 fully matching, plus 31 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag). ... Under his leadership Tracleer was built into a global brand with almost

  • New associate director at Packer Forbes New associate director at Packer Forbes

    Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • New Senior Appointment

    diabetes. She began her career in healthcare as a pharmaceutical marketeer with Merck-Serono and then joined Actelion UK as Brand Lead for its first-in-class pulmonary hypertension treatment, Tracleer.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics